MaxCyte (MXCT) Financials

$2.19 -0.06 (-2.67%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.19 +0.00 (+0.23%)

As of 05/23/2025 07:57 PM Eastern

Annual Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-41	-38	-24
Consolidated Net Income / (Loss)	-41	-38	-24
Net Income / (Loss) Continuing Operations	-41	-38	-24
Total Pre-Tax Income	-41	-38	-24
Total Operating Income	-51	-48	-27
Total Gross Profit	32	37	39
Total Revenue	39	41	44
Operating Revenue	39	41	44
Total Cost of Revenue	7.10	4.74	5.10
Operating Cost of Revenue	7.10	4.74	5.10
Total Operating Expenses	83	85	67
Selling, General & Admin Expense	30	30	26
Marketing Expense	27	27	19
Research & Development Expense	22	24	20
Depreciation Expense	4.14	3.99	2.53
Total Other Income / (Expense), net	10	10	3.79
Interest & Investment Income	10	10	3.92
Income Tax Expense	0.00	0.00	0.00
Basic Earnings per Share	($0.39)	($0.37)	($0.23)
Weighted Average Basic Shares Outstanding	104.85M	103.27M	101.70M
Diluted Earnings per Share	($0.39)	($0.37)	($0.23)
Weighted Average Diluted Shares Outstanding	104.85M	103.27M	101.70M
Weighted Average Basic & Diluted Shares Outstanding	106.03M	104.13M	102.90M

This table shows MaxCyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Consolidated Net Income / (Loss)	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Net Income / (Loss) Continuing Operations	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Total Pre-Tax Income	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Total Operating Income	-13	-14	-12	-12	-8.10	-14	-13	-13	-6.75	-7.71
Total Gross Profit	6.41	6.24	8.94	9.94	14	7.21	7.67	7.58	11	9.27
Total Revenue	8.69	8.16	10	11	16	8.00	9.04	8.58	12	11
Operating Revenue	8.69	8.16	10	11	16	8.00	9.04	8.58	12	11
Total Cost of Revenue	2.28	1.93	1.49	1.40	1.57	0.79	1.38	1.00	1.55	1.37
Operating Cost of Revenue	2.28	1.93	1.49	1.40	1.57	0.79	1.38	1.00	1.55	1.37
Total Operating Expenses	19	20	21	22	22	21	21	21	18	17
Selling, General & Admin Expense	7.21	7.75	7.64	7.10	8.09	6.82	7.66	7.50	5.65	6.44
Marketing Expense	6.47	6.21	6.62	7.37	7.20	7.05	6.44	6.30	5.38	4.51
Research & Development Expense	4.61	5.32	5.62	6.68	5.84	6.26	5.66	6.05	5.73	5.33
Depreciation Expense	1.02	1.02	1.03	1.07	1.06	1.03	0.98	0.91	0.87	0.71
Total Other Income / (Expense), net	2.30	2.50	2.59	2.75	2.82	2.70	2.56	2.30	1.94	1.28
Interest & Investment Income	2.30	2.50	2.59	2.75	2.82	2.70	2.56	2.30	1.95	1.39
Basic Earnings per Share	($0.10)	($0.11)	($0.09)	($0.09)	($0.05)	($0.11)	($0.10)	($0.11)	($0.05)	($0.06)
Weighted Average Basic Shares Outstanding	104.85M	105.11M	104.64M	104.09M	103.27M	103.45M	103.06M	102.85M	101.70M	101.81M
Weighted Average Diluted Shares Outstanding	104.85M	105.11M	104.64M	104.54M	103.27M	103.45M	103.06M	103.05M	101.70M	101.81M
Weighted Average Basic & Diluted Shares Outstanding	106.03M	105.48M	105.09M	104.54M	104.13M	103.58M	103.50M	103.05M	102.90M	102.05M

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-19	35	-37
Net Cash From Operating Activities	-28	-22	-15
Net Cash From Continuing Operating Activities	-28	-22	-15
Net Income / (Loss) Continuing Operations	-41	-38	-24
Consolidated Net Income / (Loss)	-41	-38	-24
Depreciation Expense	4.32	4.17	2.70
Amortization Expense	-5.77	-6.73	-2.67
Non-Cash Adjustments To Reconcile Net Income	16	17	11
Changes in Operating Assets and Liabilities, net	-0.75	1.91	-2.07
Net Cash From Investing Activities	6.93	55	-25
Net Cash From Continuing Investing Activities	6.93	55	-25
Purchase of Property, Plant & Equipment	-1.65	-3.70	-18
Purchase of Investments	-151	-255	-291
Sale of Property, Plant & Equipment	0.00	0.01	0.00
Sale and/or Maturity of Investments	159	314	285
Net Cash From Financing Activities	2.06	2.14	2.89
Net Cash From Continuing Financing Activities	2.06	2.14	2.89
Issuance of Common Equity	0.46	0.27	0.00
Other Financing Activities, net	1.60	1.87	2.89

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-9.07	-0.56	15	-24	-2.67	-5.39	17	27	-32	-66
Net Cash From Operating Activities	-7.82	-4.39	-4.83	-11	0.98	-8.24	-10	-4.32	-6.09	-5.92
Net Cash From Continuing Operating Activities	-7.82	-4.39	-4.83	-11	0.98	-8.24	-10	-4.32	-6.09	-5.92
Net Income / (Loss) Continuing Operations	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Consolidated Net Income / (Loss)	-11	-12	-9.38	-9.53	-5.28	-11	-11	-11	-4.81	-6.43
Depreciation Expense	1.06	1.07	1.08	1.11	1.10	1.08	1.03	0.96	0.92	0.74
Amortization Expense	-0.72	-1.39	-1.68	-1.98	-1.60	-1.48	-1.91	-1.73	-1.51	-0.95
Non-Cash Adjustments To Reconcile Net Income	4.15	4.52	3.82	3.17	5.89	1.69	4.84	4.46	6.26	3.82
Changes in Operating Assets and Liabilities, net	-1.71	2.97	1.33	-3.34	0.87	1.73	-3.55	2.86	-6.95	-3.09
Net Cash From Investing Activities	-1.67	3.61	19	-14	-4.14	2.81	27	30	-27	-61
Net Cash From Continuing Investing Activities	-1.67	3.61	19	-14	-4.14	2.81	27	30	-27	-61
Purchase of Property, Plant & Equipment	-0.15	-0.41	-0.29	-0.80	-0.92	-0.72	-0.51	-1.56	-2.19	-3.48
Purchase of Investments	-33	-39	-31	-48	-69	-81	-47	-58	-77	-82
Sale and/or Maturity of Investments	31	43	51	34	66	84	74	89	53	25
Net Cash From Financing Activities	0.41	0.23	0.71	0.70	0.49	0.04	0.16	1.46	1.23	0.44
Net Cash From Continuing Financing Activities	0.41	0.23	0.71	0.70	0.49	0.04	0.16	1.46	1.23	0.44
Issuance of Common Equity	0.19	-	0.27	0.00	0.27	-	-	0.00	-	-
Other Financing Activities, net	0.22	0.23	0.45	0.70	0.22	0.04	0.16	1.46	1.23	0.44

This table presents MaxCyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	239	268	287
Total Current Assets	172	190	252
Cash & Equivalents	28	47	11
Short-Term Investments	127	122	216
Accounts Receivable	4.68	5.78	13
Inventories, net	8.91	12	8.58
Prepaid Expenses	3.61	3.90	3.26
Plant, Property, & Equipment, net	20	24	24
Total Noncurrent Assets	48	55	11
Long-Term Investments	36	43	0.00
Other Noncurrent Operating Assets	12	12	11
Total Liabilities & Shareholders' Equity	239	268	287
Total Liabilities	33	36	33
Total Current Liabilities	16	18	15
Accounts Payable	1.36	0.74	0.29
Accrued Expenses	8.30	11	8.27
Current Deferred Revenue	5.25	5.07	6.71
Other Current Liabilities	0.86	0.77	0.16
Total Noncurrent Liabilities	17	18	17
Other Noncurrent Operating Liabilities	17	18	17
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	206	232	254
Total Preferred & Common Equity	206	232	254
Preferred Stock	0.00	0.00	0.00
Total Common Equity	206	232	254
Common Stock	423	408	392
Retained Earnings	-217	-176	-138

This table presents MaxCyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	249	251	258	267	271	282	286
Total Current Assets	173	176	179	214	237	246	252
Cash & Equivalents	37	38	22	49	55	38	43
Short-Term Investments	117	120	135	141	162	187	190
Accounts Receivable	4.56	4.58	5.99	8.17	7.61	9.29	8.21
Inventories, net	10	11	12	13	11	10	7.91
Prepaid Expenses	4.12	2.58	3.21	3.40	1.88	2.23	3.28
Plant, Property, & Equipment, net	21	22	23	24	24	25	23
Total Noncurrent Assets	55	54	56	29	10	10	11
Long-Term Investments	43	42	45	18	-	-	-
Other Noncurrent Operating Assets	12	12	11	10	10	10	11
Total Liabilities & Shareholders' Equity	249	251	258	267	271	282	286
Total Liabilities	35	30	32	33	30	34	32
Total Current Liabilities	18	12	13	17	13	17	17
Accounts Payable	1.87	0.95	1.67	0.45	1.60	3.50	2.09
Accrued Expenses	8.20	7.08	6.50	9.92	6.41	6.91	8.23
Current Deferred Revenue	6.65	3.37	4.48	5.59	4.69	5.75	6.29
Other Current Liabilities	0.91	0.88	0.83	0.70	0.50	0.48	0.15
Total Noncurrent Liabilities	18	18	18	17	17	17	15
Other Noncurrent Operating Liabilities	18	18	18	17	17	17	15
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	213	221	226	233	241	248	254
Total Preferred & Common Equity	213	221	226	233	241	248	254
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	213	221	226	233	241	248	254
Common Stock	420	416	412	404	400	397	387
Retained Earnings	-206	-195	-185	-171	-159	-149	-133

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-6.45%	-6.72%	30.59%
EBITDA Growth	-3.53%	-86.07%	-62.34%
EBIT Growth	-6.00%	-76.53%	-50.43%
NOPAT Growth	-6.00%	-76.53%	-50.43%
Net Income Growth	-8.26%	-60.89%	-23.52%
EPS Growth	-5.41%	-60.87%	-9.52%
Operating Cash Flow Growth	-27.32%	-46.70%	-38.42%
Free Cash Flow Firm Growth	-9.82%	25.85%	-120.44%
Invested Capital Growth	-23.65%	-21.36%	239.07%
Revenue Q/Q Growth	-15.29%	8.52%	5.41%
EBITDA Q/Q Growth	-7.27%	-2.53%	-11.28%
EBIT Q/Q Growth	-10.36%	-2.86%	-7.02%
NOPAT Q/Q Growth	-10.36%	-2.86%	-7.02%
Net Income Q/Q Growth	-14.88%	-1.25%	0.27%
EPS Q/Q Growth	0.00%	0.00%	-4.55%
Operating Cash Flow Q/Q Growth	-46.80%	24.58%	-53.08%
Free Cash Flow Firm Q/Q Growth	-26.37%	21.94%	0.00%
Invested Capital Q/Q Growth	-4.11%	-15.24%	23.58%
Profitability Metrics	-	-	-
Gross Margin	81.62%	88.51%	88.48%
EBITDA Margin	-136.30%	-123.17%	-61.75%
Operating Margin	-132.54%	-116.98%	-61.82%
EBIT Margin	-132.54%	-116.98%	-61.82%
Profit (Net Income) Margin	-106.29%	-91.85%	-53.25%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	80.19%	78.52%	86.15%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-194.09%	-142.15%	-111.09%
ROIC Less NNEP Spread (ROIC-NNEP)	-191.49%	-140.27%	-109.26%
Return on Net Nonoperating Assets (RNNOA)	175.36%	126.55%	101.97%
Return on Equity (ROE)	-18.73%	-15.60%	-9.12%
Cash Return on Invested Capital (CROIC)	-167.27%	-118.24%	-219.99%
Operating Return on Assets (OROA)	-20.17%	-17.41%	-9.59%
Return on Assets (ROA)	-16.17%	-13.67%	-8.26%
Return on Common Equity (ROCE)	-18.73%	-15.60%	-9.12%
Return on Equity Simple (ROE_SIMPLE)	-19.91%	-16.33%	-9.28%
Net Operating Profit after Tax (NOPAT)	-36	-34	-19
NOPAT Margin	-92.78%	-81.89%	-43.27%
Net Nonoperating Expense Percent (NNEP)	-2.60%	-1.88%	-1.83%
Return On Investment Capital (ROIC_SIMPLE)	-17.38%	-14.56%	-
Cost of Revenue to Revenue	18.38%	11.49%	11.52%
SG&A Expenses to Revenue	76.87%	72.83%	58.36%
R&D to Revenue	57.54%	57.69%	44.09%
Operating Expenses to Revenue	214.16%	205.50%	150.30%
Earnings before Interest and Taxes (EBIT)	-51	-48	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-53	-51	-27
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.13	2.10	2.19
Price to Tangible Book Value (P/TBV)	2.13	2.10	2.19
Price to Revenue (P/Rev)	11.36	11.79	12.59
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	15.55	13.16	12.39
Enterprise Value to Revenue (EV/Rev)	6.43	6.67	7.45
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.92	-0.90	-0.93
Leverage Ratio	1.16	1.14	1.10
Compound Leverage Factor	0.93	0.90	0.95
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	6.90	7.50	10.39
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	10.88	10.65	16.35
Quick Ratio	10.09	9.75	15.58
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-31	-28	-38
Operating Cash Flow to CapEx	-1,672.32%	-587.54%	-80.01%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-298.64
Operating Cash Flow to Interest Expense	0.00	0.00	-116.40
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-261.89
Efficiency Ratios	-	-	-
Asset Turnover	0.15	0.15	0.16
Accounts Receivable Turnover	7.39	4.38	4.43
Inventory Turnover	0.67	0.46	0.74
Fixed Asset Turnover	1.79	1.75	2.82
Accounts Payable Turnover	6.76	9.16	4.83
Days Sales Outstanding (DSO)	49.42	83.39	82.32
Days Inventory Outstanding (DIO)	543.46	800.89	493.50
Days Payable Outstanding (DPO)	54.00	39.83	75.62
Cash Conversion Cycle (CCC)	538.88	844.44	500.20
Capital & Investment Metrics	-	-	-
Invested Capital	16	21	27
Invested Capital Turnover	2.09	1.74	2.57
Increase / (Decrease) in Invested Capital	-4.95	-5.69	19
Enterprise Value (EV)	249	276	330
Market Capitalization	439	487	557
Book Value per Share	$1.96	$2.24	$2.49
Tangible Book Value per Share	$1.96	$2.24	$2.49
Total Capital	206	232	254
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-190	-211	-227
Capital Expenditures (CapEx)	1.65	3.69	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.43	4.05	9.50
Debt-free Net Working Capital (DFNWC)	156	172	237
Net Working Capital (NWC)	156	172	237
Net Nonoperating Expense (NNE)	5.22	4.11	4.42
Net Nonoperating Obligations (NNO)	-190	-211	-227
Total Depreciation and Amortization (D&A)	-1.45	-2.55	0.03
Debt-free, Cash-free Net Working Capital to Revenue	3.69%	9.81%	21.46%
Debt-free Net Working Capital to Revenue	403.63%	417.41%	535.10%
Net Working Capital to Revenue	403.63%	417.41%	535.10%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.39)	($0.37)	($0.23)
Adjusted Weighted Average Basic Shares Outstanding	104.85M	103.27M	101.70M
Adjusted Diluted Earnings per Share	($0.39)	($0.37)	($0.23)
Adjusted Weighted Average Diluted Shares Outstanding	104.85M	103.27M	101.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.03M	104.13M	102.90M
Normalized Net Operating Profit after Tax (NOPAT)	-36	-34	-19
Normalized NOPAT Margin	-92.78%	-81.89%	-43.27%
Pre Tax Income Margin	-106.29%	-91.85%	-53.25%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	-215.44
NOPAT to Interest Expense	0.00	0.00	-150.81
EBIT Less CapEx to Interest Expense	0.00	0.00	-360.93
NOPAT Less CapEx to Interest Expense	0.00	0.00	-296.30
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-44.51%	2.00%	15.33%	32.25%	26.10%	-24.79%	-5.88%	-25.99%	22.37%	4.97%
EBITDA Growth	-46.10%	-0.15%	9.95%	5.73%	-17.11%	-81.20%	-66.88%	-276.42%	-60.62%	-273.94%
EBIT Growth	-59.35%	-0.72%	8.45%	6.85%	-19.92%	-80.91%	-49.60%	-216.85%	-36.23%	-215.69%
NOPAT Growth	-59.35%	-0.72%	8.45%	6.85%	-19.92%	-80.91%	-49.60%	-216.85%	-36.23%	-215.69%
Net Income Growth	-100.78%	-2.72%	10.82%	12.46%	-9.73%	-74.88%	-27.26%	-167.55%	1.33%	-140.03%
EPS Growth	0.00%	0.00%	10.00%	0.00%	0.00%	-83.33%	-25.00%	0.00%	-25.00%	-100.00%
Operating Cash Flow Growth	-897.25%	46.70%	52.16%	-144.31%	116.12%	-39.13%	-1,200.04%	-17.05%	-533.83%	-757.56%
Free Cash Flow Firm Growth	-20,694.44%	86.06%	72.73%	50.32%	100.08%	30.93%	-9.78%	-11.38%	0.00%	-88.35%
Invested Capital Growth	-23.65%	-32.52%	-13.76%	2.80%	-21.36%	14.67%	56.84%	68.00%	239.07%	161.88%
Revenue Q/Q Growth	6.47%	-21.72%	-8.05%	-27.59%	95.71%	-11.49%	5.45%	-30.97%	16.73%	10.77%
EBITDA Q/Q Growth	12.63%	-14.36%	4.40%	-46.24%	40.11%	-2.83%	-0.09%	-90.01%	7.34%	5.30%
EBIT Q/Q Growth	8.20%	-17.42%	2.50%	-51.63%	41.97%	-6.72%	0.80%	-95.20%	12.46%	11.75%
NOPAT Q/Q Growth	8.20%	-17.42%	2.50%	-51.63%	41.97%	-6.72%	0.80%	-95.20%	12.46%	11.75%
Net Income Q/Q Growth	8.31%	-23.27%	1.59%	-80.51%	53.09%	-7.03%	3.40%	-126.25%	25.24%	22.11%
EPS Q/Q Growth	0.00%	-22.22%	0.00%	0.00%	0.00%	-10.00%	0.00%	0.00%	16.67%	25.00%
Operating Cash Flow Q/Q Growth	-78.11%	9.16%	54.24%	-1,176.09%	111.91%	18.48%	-133.70%	28.96%	-2.79%	-744.57%
Free Cash Flow Firm Q/Q Growth	-126.20%	63.61%	46.40%	-45,646.57%	100.15%	28.84%	2.34%	20.85%	-25.55%	-13.11%
Invested Capital Q/Q Growth	-4.11%	-22.27%	-9.93%	13.72%	-15.24%	-0.67%	7.37%	-13.00%	23.58%	35.86%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	73.76%	76.38%	85.73%	87.63%	89.96%	90.09%	84.78%	88.34%	87.55%	87.14%
EBITDA Margin	-144.49%	-176.07%	-120.52%	-115.91%	-54.87%	-179.32%	-154.35%	-162.62%	-59.08%	-74.43%
Operating Margin	-148.42%	-172.13%	-114.76%	-108.23%	-51.68%	-174.31%	-144.56%	-153.66%	-54.34%	-72.46%
EBIT Margin	-148.42%	-172.13%	-114.76%	-108.23%	-51.68%	-174.31%	-144.56%	-153.66%	-54.34%	-72.46%
Profit (Net Income) Margin	-121.92%	-141.56%	-89.89%	-83.99%	-33.69%	-140.57%	-116.24%	-126.89%	-38.72%	-60.45%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	82.14%	82.24%	78.33%	77.60%	65.19%	80.64%	80.41%	82.58%	71.25%	83.42%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-217.35%	-265.56%	-157.59%	-142.08%	-62.80%	-200.73%	-202.15%	-240.12%	-97.66%	-143.07%
ROIC Less NNEP Spread (ROIC-NNEP)	-216.57%	-264.71%	-157.11%	-141.64%	-62.98%	-200.06%	-201.55%	-239.42%	-97.62%	-142.65%
Return on Net Nonoperating Assets (RNNOA)	198.33%	240.19%	141.37%	127.61%	56.82%	181.09%	185.08%	222.07%	91.11%	134.46%
Return on Equity (ROE)	-19.02%	-25.37%	-16.22%	-14.47%	-5.99%	-19.64%	-17.07%	-18.05%	-6.55%	-8.61%
Cash Return on Invested Capital (CROIC)	-167.27%	-118.12%	-125.12%	-144.00%	-118.24%	-155.79%	-184.19%	-188.56%	-219.99%	0.00%
Operating Return on Assets (OROA)	-22.58%	-30.46%	-19.95%	-17.68%	-7.69%	-23.98%	-20.97%	-22.14%	-8.43%	-10.79%
Return on Assets (ROA)	-18.55%	-25.05%	-15.63%	-13.72%	-5.01%	-19.34%	-16.86%	-18.29%	-6.00%	-9.00%
Return on Common Equity (ROCE)	-19.02%	-25.37%	-16.22%	-14.47%	-5.99%	-19.64%	-17.07%	-18.05%	-6.55%	-8.61%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-16.75%	-16.01%	-16.15%	0.00%	-16.05%	-13.54%	-12.26%	0.00%	-9.29%
Net Operating Profit after Tax (NOPAT)	-9.03	-9.84	-8.38	-8.59	-5.67	-9.77	-9.15	-9.22	-4.73	-5.40
NOPAT Margin	-103.90%	-120.49%	-80.33%	-75.76%	-36.18%	-122.02%	-101.20%	-107.56%	-38.04%	-50.72%
Net Nonoperating Expense Percent (NNEP)	-0.78%	-0.85%	-0.48%	-0.44%	0.18%	-0.67%	-0.60%	-0.70%	-0.03%	-0.42%
Return On Investment Capital (ROIC_SIMPLE)	-4.38%	-	-	-	-2.44%	-	-	-	-	-
Cost of Revenue to Revenue	26.24%	23.62%	14.27%	12.37%	10.04%	9.91%	15.22%	11.66%	12.45%	12.86%
SG&A Expenses to Revenue	82.90%	94.87%	73.25%	62.63%	51.62%	85.21%	84.74%	87.44%	45.48%	60.55%
R&D to Revenue	53.08%	65.12%	53.88%	58.88%	37.29%	78.26%	62.63%	70.51%	46.10%	50.03%
Operating Expenses to Revenue	222.18%	248.52%	200.49%	195.86%	141.64%	264.41%	229.35%	242.00%	141.90%	159.60%
Earnings before Interest and Taxes (EBIT)	-13	-14	-12	-12	-8.10	-14	-13	-13	-6.75	-7.71
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-14	-13	-13	-8.60	-14	-14	-14	-7.34	-7.92
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.13	1.92	1.85	1.93	2.10	1.38	1.96	2.06	2.19	2.60
Price to Tangible Book Value (P/TBV)	2.13	1.92	1.85	1.93	2.10	1.38	1.96	2.06	2.19	2.60
Price to Revenue (P/Rev)	11.36	8.96	9.02	9.90	11.79	8.49	11.63	12.35	12.59	15.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	15.55	12.73	9.79	9.82	13.16	4.62	10.33	12.29	12.39	19.88
Enterprise Value to Revenue (EV/Rev)	6.43	4.65	4.62	5.31	6.67	3.00	6.31	6.90	7.45	10.20
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.92	-0.91	-0.90	-0.90	-0.90	-0.91	-0.92	-0.93	-0.93	-0.94
Leverage Ratio	1.16	1.15	1.13	1.14	1.14	1.13	1.13	1.12	1.10	1.09
Compound Leverage Factor	0.95	0.95	0.89	0.88	0.74	0.91	0.91	0.93	0.79	0.91
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	7.42	6.53	7.85	8.07	8.00	5.77	9.55	9.29	10.62	12.80
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.88	9.81	14.31	13.26	10.65	12.87	17.92	14.81	16.35	15.05
Quick Ratio	10.09	8.99	13.19	12.13	9.75	11.92	16.94	14.06	15.58	14.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.08	-1.80	-4.95	-9.24	0.02	-13	-18	-19	-24	-19
Operating Cash Flow to CapEx	-5,320.41%	-1,081.53%	-1,644.22%	-1,313.93%	107.21%	-1,144.17%	-1,993.10%	-279.15%	-277.36%	-170.25%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-161.36
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-51.04
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-81.02
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.15	0.18	0.17	0.16	0.15	0.14	0.15	0.14	0.16	0.15
Accounts Receivable Turnover	7.39	7.17	7.46	5.77	4.38	4.65	5.41	4.60	4.43	5.93
Inventory Turnover	0.67	0.56	0.47	0.46	0.46	0.46	0.56	0.60	0.74	0.79
Fixed Asset Turnover	1.79	2.04	1.97	1.85	1.75	1.63	1.81	2.16	2.82	2.82
Accounts Payable Turnover	6.76	5.53	4.11	1.99	9.16	3.72	2.61	1.28	4.83	3.40
Days Sales Outstanding (DSO)	49.42	50.93	48.95	63.31	83.39	78.55	67.47	79.28	82.32	61.57
Days Inventory Outstanding (DIO)	543.46	654.56	769.97	788.35	800.89	791.31	646.47	610.57	493.50	460.65
Days Payable Outstanding (DPO)	54.00	66.00	88.73	183.60	39.83	98.06	140.01	285.16	75.62	107.34
Cash Conversion Cycle (CCC)	538.88	639.50	730.20	668.05	844.44	771.80	573.93	404.70	500.20	414.89
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	17	21	24	21	25	25	23	27	22
Invested Capital Turnover	2.09	2.20	1.96	1.88	1.74	1.65	2.00	2.23	2.57	2.82
Increase / (Decrease) in Invested Capital	-4.95	-8.03	-3.42	0.65	-5.69	3.16	9.01	9.38	19	13
Enterprise Value (EV)	249	212	210	234	276	114	257	285	330	428
Market Capitalization	439	409	410	436	487	323	473	509	557	661
Book Value per Share	$1.96	$2.03	$2.12	$2.17	$2.24	$2.25	$2.34	$2.41	$2.49	$2.50
Tangible Book Value per Share	$1.96	$2.03	$2.12	$2.17	$2.24	$2.25	$2.34	$2.41	$2.49	$2.50
Total Capital	206	213	221	226	232	233	241	248	254	254
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-190	-197	-200	-203	-211	-209	-216	-225	-227	-233
Capital Expenditures (CapEx)	0.15	0.41	0.29	0.80	0.92	0.72	0.51	1.55	2.19	3.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.43	1.46	6.04	7.68	4.05	7.45	7.31	5.15	9.50	2.63
Debt-free Net Working Capital (DFNWC)	156	155	163	165	172	198	223	230	237	236
Net Working Capital (NWC)	156	155	163	165	172	198	223	230	237	236
Net Nonoperating Expense (NNE)	1.57	1.72	1.00	0.93	-0.39	1.48	1.36	1.66	0.08	1.04
Net Nonoperating Obligations (NNO)	-190	-197	-200	-203	-211	-209	-216	-225	-227	-233
Total Depreciation and Amortization (D&A)	0.34	-0.32	-0.60	-0.87	-0.50	-0.40	-0.89	-0.77	-0.59	-0.21
Debt-free, Cash-free Net Working Capital to Revenue	3.69%	3.19%	13.30%	17.44%	9.81%	19.58%	17.96%	12.48%	21.46%	6.27%
Debt-free Net Working Capital to Revenue	403.63%	340.54%	359.53%	374.99%	417.41%	519.61%	549.13%	557.10%	535.10%	560.89%
Net Working Capital to Revenue	403.63%	340.54%	359.53%	374.99%	417.41%	519.61%	549.13%	557.10%	535.10%	560.89%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.10)	($0.11)	($0.09)	($0.09)	($0.05)	($0.11)	($0.10)	($0.11)	($0.05)	($0.06)
Adjusted Weighted Average Basic Shares Outstanding	104.85M	105.11M	104.64M	104.09M	103.27M	103.45M	103.06M	102.85M	101.70M	101.81M
Adjusted Diluted Earnings per Share	$0.00	($0.11)	($0.09)	$0.00	$0.00	($0.11)	($0.10)	($0.11)	($0.05)	($0.06)
Adjusted Weighted Average Diluted Shares Outstanding	104.85M	105.11M	104.64M	104.54M	103.27M	103.45M	103.06M	102.85M	101.70M	101.81M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.03M	105.48M	105.09M	104.54M	104.13M	103.58M	103.50M	103.05M	102.90M	102.05M
Normalized Net Operating Profit after Tax (NOPAT)	-9.03	-9.84	-8.38	-8.59	-5.67	-9.77	-9.15	-9.22	-4.73	-5.40
Normalized NOPAT Margin	-103.90%	-120.49%	-80.33%	-75.76%	-36.18%	-122.02%	-101.20%	-107.56%	-38.04%	-50.72%
Pre Tax Income Margin	-121.92%	-141.56%	-89.89%	-83.99%	-33.69%	-140.57%	-116.24%	-126.89%	-38.72%	-60.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-66.48
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-46.54
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-96.46
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-76.52
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About MaxCyte's Financials

When does MaxCyte's fiscal year end?

According to the most recent income statement we have on file, MaxCyte's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has MaxCyte's net income changed over the last 2 years?

MaxCyte's net income appears to be on an upward trend, with a most recent value of -$41.06 million in 2024, rising from -$23.57 million in 2022. The previous period was -$37.92 million in 2023. Find out what analysts predict for MaxCyte in the coming months.

What is MaxCyte's operating income?

MaxCyte's total operating income in 2024 was -$51.20 million, based on the following breakdown:

Total Gross Profit: $31.53 million
Total Operating Expenses: $82.72 million

How has MaxCyte revenue changed over the last 2 years?

Over the last 2 years, MaxCyte's total revenue changed from $44.26 million in 2022 to $38.63 million in 2024, a change of -12.7%.

How much debt does MaxCyte have?

MaxCyte's total liabilities were at $33.22 million at the end of 2024, a 8.0% decrease from 2023, and a 1.6% increase since 2022.

How much cash does MaxCyte have?

In the past 2 years, MaxCyte's cash and equivalents has ranged from $11.07 million in 2022 to $46.51 million in 2023, and is currently $27.88 million as of their latest financial filing in 2024.

How has MaxCyte's book value per share changed over the last 2 years?

Over the last 2 years, MaxCyte's book value per share changed from 2.49 in 2022 to 1.96 in 2024, a change of -21.4%.

Related Companies

This page (NASDAQ:MXCT) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Financials

Frequently Asked Questions About MaxCyte's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Financials

Annual Income Statements for MaxCyte

Quarterly Income Statements for MaxCyte

Annual Cash Flow Statements for MaxCyte

Quarterly Cash Flow Statements for MaxCyte

Annual Balance Sheets for MaxCyte

Quarterly Balance Sheets for MaxCyte

Annual Metrics And Ratios for MaxCyte

Quarterly Metrics And Ratios for MaxCyte

Frequently Asked Questions About MaxCyte's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools